Compendia Bioscience scores $1.3M investment from NIH

Wednesday, September 8, 2010 | Source: Concentrate
The National Institute of Health is sending $1.3 million in seed capital toward Compendia Bioscience to help it further its cancer research.

The cash comes from the Small Business Innovation Research program's Fast Track funds, which aim to bridge the financing gap for high-tech firms, such as bio-tech companies, to develop and commercialize their technologies. The Ann Arbor-based company plans to use its seven figures' worth of cash to incorporate micro-RNA data and analyses into the Oncomine platform.

Micro-RNA data is clearly correlated with cancer diagnosis, staging, and prognosis. This is valuable because cancer is a complex disease in which all of the causes and effects are not well understood. Making the micro-RNA information accessible on the Oncomine platform will allow it to become a more sophisticated analysis engine and a powerful web application for data mining and visualization.

The 4-year-old Compendia Bioscience specializes in research-centric software development. Its products help researchers sift through mounds of biological data, enabling them to find answers to clinical questions quicker. It has attracted millions of dollars in venture capital, including $1.7 million from Michigan's 21st Century Jobs Fund in 2008.

Source: Compendia Bioscience
Writer: Jon Zemke
Enjoy this story? Sign up for free solutions-based reporting in your inbox each week.

Related Tags

Government, Investment, Medical Research 

Recommended Content

Related Company

  • Compendia Bioscience, Inc.
    110 Miller Ave. Floor 2
    Ann Arbor, Michigan 48104 Website
    Compendia Bioscience, Inc. gathers the world’s high-throughput biology data, making that data interpretable and applicable in target identification/validation, drug development, and clinical research to improve the lives of patients.
Sponsored By
Regions
Focus Areas
Copyright © Issue Media Group. All rights reserved.